Ivo Abraham, PhD, RN

Professor of Practice

Ivo Abraham is a professor (part-time) in the Department of Pharmacy Practice. He has also served on the faculty of Case Western Reserve University (Cleveland, Ohio), University of Virginia (Charlottesville, Va.), and (part-time) Katholieke Universiteit Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, Fla.), Rijksuniversiteit Groningen (Groningen, The Netherlands), University of Pennsylvania (Philadelphia, Penn.), and Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan).  He has lectured, consulted, and conducted research throughout the Americas, Europe, the Asia-Pacific region, and Africa. Being part-time, he divides his time between the University of Arizona and Matrix45, a biopharmaceutical research and consulting company, where he serves as chief scientist.

For the past decade or so, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research, in particular how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes. However, instead of merely evaluating effectiveness (does the treatment work?), the work of his research group addresses the equally important questions of when does the treatment work (and when not), what influences whether the treatment works, why does the treatment work in some patients but not in others, why does the treatment work with some clinicians but not with others, why is the treatment tolerated by some patients but not by others, and how much of patient outcomes is related to patient vs. clinician or treatment center?  In this process, his group uses a comprehensive framework of treatment patterns and outcomes assessment, vulnerability profiling, hierarchical modeling, (non-)responder analysis, and pharmacovigilance and drawing methodologies and statistical models from other disciplines into biomedical research.  

More recently, frustrated by the abundance of evidence but clinicians’ persistent low adoption of evidence-based guidelines, he and his colleagues started examining how practicing in accordance with evidence-based guidelines is directly associated with patient outcomes.

He has (co-)authored 260+ articles and 60+ chapters, and has (co-)edited 29 books, monographs, and journal issues. Since 1984, his research has been funded by federal funding agencies, foundations, and corporations.   He has served as appointed ad hoc reviewer for the NIH, the NIMH, and the AHRQ. He currently serves as an expert adviser to the Innovative Medicines Initiative, a joint 2 billion euro undertaking of the European Union and the biopharmaceutical industry to stimulate innovation in human therapeutics.

His educational and scientific honors and awards include an Invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008), which he conducted at Hyogo University and Aomori University.

View UA Profile

Education & Post Graduate Training: 

BS, Nursing, Katholieke Hogeschool Leuven (Leuven, Belgium)
MS, Psychiatric-Mental Health Nursing, University of Michigan
PhD, Clinical Research, University of Michigan 

Select Publications

2019

Bime C, Casanova N, Oita RC, et al. "Development of a biomarker mortality risk model in acute respiratory distress syndrome." Crit Care. 2019;23(1):410. PMCID: PMC6916252  PMID: 31842964
Crocker RL, Hurwitz JT, Grizzle AJ, et al. "Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up." Evid Based Complement Alternat Med. 2019;2019:8595409. PMCID: PMC6617880  PMID: 31346339
Almutairi AR, Alkhatib N, Martin J, et al. "Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis." Crit Rev Oncol Hematol. 2019;142:16-25. PMID: 31326706
Tate WR, Abraham I, Cranmer LD. "Center-Specific Modeling Predicts Cancer Trial Accrual More Accurately Than Investigators and Random Effects Modeling at 16 Cancer Centers." JCO Clin Cancer Inform. 2019;3:1-12. PMID: 31173517
Yun S, Sharma R, Chan O, et al. "Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)." Leuk Res. 2019;84:106194. PMCID: PMC7375354  PMID: 31357093
Oh M, McBride A, Yun S, et al. "Response to Katona et al." J Natl Cancer Inst. 2019;111(5):524-525. PMID: 30715401
Oh M, Alkhushaym N, Fallatah S, et al. "The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis." Prostate. 2019;79(8):880-895. PMID: 30900310
Alhifany AA, Almutairi AR, Almangour TA, et al. "Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials." BMJ Open. 2019;9(11):e031145. PMCID: PMC6858162  PMID: 31699731

2018

Scholpa NE, Lynn MK, Corum D, Boger HA, Schnellmann RG. "5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease." Br. J. Pharmacol.. 2018;175(2):348-358. PMID: 29057453
Oh M, McBride A, Yun S, et al. "BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis." J. Natl. Cancer Inst.. 2018;110(11):1178-1189. PMID: 30380096